Lv1
40 积分 2021-09-26 加入
A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma
14天前
已完结
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
2个月前
已完结
NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
3个月前
已完结
Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer
3个月前
已完结
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
6个月前
已完结
Polypharmacology – Foe or Friend?
8个月前
已完结
Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2
11个月前
已完结
EZH2 promotes proliferation and invasiveness of prostate cancer cells
11个月前
已完结
EZH1/2 as targets for cancer therapy
11个月前
已完结
皖公网安备34019202002308
